India Exchange Filings

Suven Life Sciences CTAD-2026 Presentation Announcement

Suven Life Sciences Ltd presents Masupirdine and Tenaclidine data at CTAD-2026, with Masupirdine Phase 3 results expected in Q2 2027

  • Masupirdine presentation covers baseline demographic and clinical characteristics; global Phase 3 enrollment is complete.
  • Tenaclidine presentation covers Phase 1 safety, tolerability and pharmacokinetics.
  • Suven said Tenaclidine’s clinical findings support advancing to patient studies.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.